Deutsche Bank reissued their buy rating on shares of Shire (LON:SHP) in a research note issued to investors on Tuesday morning. Deutsche Bank currently has a GBX 3,559 ($50.96) target price on the biopharmaceutical company’s stock.
A number of other research firms also recently commented on SHP. Shore Capital reaffirmed a buy rating on shares of Shire in a research report on Friday, February 23rd. Societe Generale dropped their target price on shares of Shire from GBX 8,000 ($114.55) to GBX 7,500 ($107.39) and set a buy rating on the stock in a research report on Wednesday, February 28th. Morgan Stanley reissued an overweight rating and set a GBX 5,700 ($81.62) price objective on shares of Shire in a research report on Thursday, February 15th. HSBC reissued a hold rating on shares of Shire in a research report on Thursday, March 29th. Finally, Sanford C. Bernstein set a GBX 4,400 ($63.00) price objective on shares of Shire and gave the stock a buy rating in a research report on Tuesday, April 3rd. Five research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of GBX 4,550.80 ($65.16).
LON SHP opened at GBX 3,621 ($51.85) on Tuesday. Shire has a 12 month low of GBX 2,940.50 ($42.10) and a 12 month high of GBX 5,021 ($71.89).
The company also recently announced a dividend, which will be paid on Tuesday, April 24th. Stockholders of record on Thursday, March 8th will be paid a GBX 21.46 ($0.31) dividend. This represents a dividend yield of 0.67%. The ex-dividend date of this dividend is Thursday, March 8th. This is a boost from Shire’s previous dividend of $3.85.
ILLEGAL ACTIVITY WARNING: “Shire’s (SHP) “Buy” Rating Reaffirmed at Deutsche Bank” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/18/shires-shp-buy-rating-reaffirmed-at-deutsche-bank.html.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.